Company

BELLUS Health Inc.

Headquarters: Laval, QC, Canada

Employees: 40

CEO: Mr. Roberto Francesco Bellini

TSX: BLU

Market Cap

C$2.47 Billion

CAD as of June 1, 2023

US$1.86 Billion

Market Cap History

BELLUS Health Inc. market capitalization over time

Evolution of BELLUS Health Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of BELLUS Health Inc.

Detailed Description

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.

Top 1-year algo backtest: +327.04%

$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Financials

Last Financial Reports Date March 31, 2023
Revenue TTM C$16,000
EBITDA C$0
Gross Profit TTM C$0
Profit Margin %
Operating Margin -474637.50%
Quarterly Revenue Growth -25.00%
Financial Reports & Statistics

Stocks & Indices

BELLUS Health Inc. has the following listings and related stock indices.


Stock: TSX: BLU wb_incandescent

Stock: NASDAQ: BLU wb_incandescent

Stock: FSX: BHN0 wb_incandescent

Details

Headquarters:

275 Armand-Frappier Boulevard

Laval, QC H7V 4A7

Canada

Phone: 450 680 4500

Fax: 450 680 4501